EUCTR2019-000914-12-DE进行中（未招募）1 期
Gazyvaro Targeting Tumor Promoting, Regulatory B-cells in Solid Tumors
niversity of Cologne0 个研究点目标入组 27 人开始时间: 2020年1月16日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 27
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.18 years of age or older
- •2.Written, signed, and dated informed consent before conduct of any study-specific procedure
- •3.ECOG performance status of 0-2
- •4.Life expectancy of more than 6 months
- •5.Advanced disease:
- •a.Prostate Cancer: Castration resistant metastatic disease, at least 2 prior lines of treatment have failed, known PSA serum level at baseline
- •b.Melanoma: Unresectable stage III melanoma with N3 macroscopic lymph nodes or in-transit/satellite metastases or stage IV melanoma after at least 2 lines of standard treatment including checkpoint blockade (CTLA-4 and PD-L1) and BRAF inhibitor in BRAF mutant tumors. Known PD-L1, PD-1 and BRAF status at baseline level.
- •c.CTCL: = stage IIB, = 2 previous lines of treatment (1 skin directed, 1 systemic); continuing skin directed therapy
- •d.Measurable lesion according to RECIST 1.1/iRECIST/CTCL consensus criteria
- •6.Recent biopsy confirming the diagnosis (= 4 weeks old)
- •7.Adequate organ function
- •a.WBC = 2500/µL
- •b.ANC = 1000/µL
- •c.Platelets = 50 x 103/µL
- •d.Hemoglobin = 8 g/dL
- •e.Estimated glomerular filtration rate =30 mL/min/1.73m2 calculated with CKD-EPI or FAS
- •f.AST = 2.5 x ULN for patients without liver metastasis, = 5 x ULN for patients with liver metastasis
- •g.Bilirubin = 1.5 x ULN, (except patients with Gilbert’s Syndrome), total bilirubin less than 3.0 mg/dL)
- •8.Reproductive Status
- •a.Women of childbearing potential (WOCBP) must use appropriate method(s) of contraception and must agree to use adequate method to avoid pregnancy for at least 5 months after the last dose of Atezolizumab and 18 months after the last dose of Obinutuzumab..
- •b.WOCB must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of ß-HCG) within one until two weeks prior to the start of obinutuzumab / atezolizumab at time of treatment.
- •c.Men who are sexually active with WOCBP must use any contraceptive method with a failure rate of less than 1% per year. Men receiving obinutuzumab /atezolizumab and who are sexually active with WOCBP must be willing to adhere to contraception for a period of 5 months post atezolizumab and 18 months post obinutuzumab treatment treatment completion.
- •d.Evidence of post-menopausal status or negative urinary or serum pregnancy test for female pre-menopausal patients. Women will be considered post-menopausal if they have been amenorrheic for 12 months without an alternative medical cause. The following age-specific requirements apply:
- •-Women >50 years of age would be considered postmenopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and if they have luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution or underwent surgical sterilization (bilateral oophorectomy or hysterectomy).
- •-Women =50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments, had radiation-induced menopause with last menses >1 year ago, had chemotherapy-induced menopause with last menses >1 year ago, or underwent surgical sterilization (bilateral oophorectomy, bilateral salpingectomy or hysterectomy).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 20
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 7
排除标准
- •1.Patients, which have treatment alternative other than best supportive care, are not eligible for this clinical trial.
- •2.Any medical, mental or psychological condition which in the opinion of the investigator would not permit the patient to understand the patient information or complete the study.
- •3.Concurrent systemic cancer related treatment or immune therapy (including antibodies, immuncheckpoint inhibitors or other immunomodulating agents), ongoing chemotherapy or therapy with any anticancer drug not indicated in the study protocol
- •4.Prior treatment with atezolizumab or obinutuzumab
- •5.Any investigational agent(s) within 4 weeks prior to study entry
- •6.Immuncheckpoint inhibitors, other immunomodulating agents or chemotherapy administered less than 4 weeks before first intake of study drug.
- •7.Active or history of autoimmune disease that requires ongoing systemic steroids (=10mg daily prednisone equivalent) or immunosuppressive medications (including but not limited to corticosteroids, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor) within 2 weeks prior to study entry. Exceptions are:
- •a. vitiligo or resolved childhood asthma.
- •b.Inhaled or topical steroids
- •adrenal replacement steroid doses =10 mg daily prednisone equivalent are permitted in the absence of active autoimmune disease.
- •8.New and active brain metastasis or meningeosis neoplastica. Note: Patients with stable or treated brain metastasis (e.g. after resection, intra or radiation therapy) are allowed to participate in this trial
- •9.Active and/or chronic viral, bacterial or fungal infection such as hepatitis B, hepatitis C, hepatitis E, HIV or tuberculosis
- •10.Active uncontrolled acute life-threatening bacterial, viral or fungal infection (e.g. blood culture positive = 72 treatment start)
- •11.History of another primary malignancy except for
- •a.Malignancy treated with curative intent and with no known active disease =5 years before the first dose of IP and of low potential risk for recurrence
- •b.Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease
- •c.Adequately treated carcinoma in situ without evidence of disease
- •12.Patients with severe cardiovascular disease (e.g. NYHA functional class III or IV, myocardial infarction within 6 months before inclusion, ventricular tachyarrhythmia requiring ongoing treatment, unstable angina pectoris)
- •13.History of active primary immunodeficiency
- •14.Major surgery (defined as opening at least one body cavity) within 4 weeks prior to signing of informed consent
- •15.History of idiopathic pulmonary fibrosis, drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening CT scan
- •16.Pregnant or breastfeeding females
- •17.Current treatment within another therapeutic clinical trial with experimental and not approved drugs and treatment combinations
- •18.Prior allogeneic bone marrow transplantation or prior solid organ transplantation
- •19.Allergies and Adverse Drug Reaction
- •a.History of allergy to study drug components
- •b.History of severe hypersensitivity reaction to any monoclonal antibody
- •c.History of severe adverse drug reaction (= grade 3) of any monotherapy with anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA4 antibodies or other immune checkpoint inhibitors
- •Note: Severe adverse drug reaction (= grade 3) with comination treatment of anti-PD-1, anti-PD-L1, anti-PD-L2 together with anti-CTLA4 antibodies, but resolved withou
研究者
相似试验
进行中（未招募）
1 期
Gazyvaro Targeting Tumor Promoting, Regulatory B cells in Solid TumorsDRKS00017290niversität zu Köln1
进行中（未招募）
1 期
A study of the use of apalutamide (ARN509) to reduce tumour volumes in men on active surveillance for prostate cancerEUCTR2017-001700-29-GBCambridge University Hospitals NHS Foundation Trust & The University of Cambridge10
招募中
不适用
Co-stimulatory and -inhibitory molecules on tumor-infiltrating lymphocytes from cholangiocarcinomabile duct cancer10019815cholangiocarcinomaNL-OMON43309Stichting Leveronderzoek102
招募中
不适用
Granulosa cell tumours: a step towards targeted therapyOvarian cancerNL-OMON54607niversitair Medisch Centrum Utrecht300
进行中（未招募）
1 期
Targeting triple negative BREAst cancer metabolism with a combination of chemotherapy and a diet mimicking FASTing plus/minus metformin in the preoperative setting: the BREAKFAST trialTargeting triple negative BREAst cancerMedDRA version: 21.0Level: LLTClassification code 10025541Term: Malignant breast neoplasmSystem Organ Class: 100000004864EUCTR2019-003093-13-ITFONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI90